Seegene Gestione

Criteri Gestione verificati 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jong-Yoon Chun

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	25.4%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi • Mar 27

Seegene, Inc. (KOSDAQ:096530) Shares Fly 25% But Investors Aren't Buying For Growth

Seegene, Inc. ( KOSDAQ:096530 ) shareholders have had their patience rewarded with a 25% share price jump in the last...

Articolo di analisi • Jan 08

Seegene, Inc. (KOSDAQ:096530) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Seegene, Inc. ( KOSDAQ:096530 ) shareholders would be excited to see that the share price has had a great month...

Articolo di analisi • Nov 22

Investors Shouldn't Be Too Comfortable With Seegene's (KOSDAQ:096530) Earnings

Despite posting some strong earnings, the market for Seegene, Inc.'s ( KOSDAQ:096530 ) stock hasn't moved much. Our...

Articolo di analisi • Nov 12

Is Seegene (KOSDAQ:096530) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Articolo di analisi • Aug 10

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Seegene, Inc. ( KOSDAQ:096530 ) shareholders would be excited to see that the share price has had a great month...

Articolo di analisi • Mar 07

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

Key Insights Seegene's estimated fair value is ₩22,248 based on 2 Stage Free Cash Flow to Equity Current share price of...

Articolo di analisi • May 06

Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

Does the May share price for Seegene, Inc. ( KOSDAQ:096530 ) reflect what it's really worth? Today, we will estimate...

AMMINISTRATORE DELEGATO

Jong-Yoon Chun (69 yo)

no data

Mandato

Dr. Jong-Yoon Chun founded Seegene, Inc. in 2000 and serves as its Chief Executive Officer and Chief Technology Officer. Dr. Chun serves as Director at Seegene, Inc. and serves as its Chairman of the Board...

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/08/04 20:27
Prezzo dell'azione a fine giornata	2026/08/04 00:00
Utili	2026/03/31
Utili annuali	2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Seegene, Inc. è coperta da 15 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
David Lee	CLSA
Jonghyun Park	DAOL Investment & Securities Co., Ltd.
Jinhee Kwak	Eugene Investment & Securities Co Ltd.

Seegene Gestione

Criteri Gestione verificati 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Seegene, Inc., Annual General Meeting, Mar 27, 2026

Seegene, Inc., Annual General Meeting, Mar 28, 2025

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Seegene Inc. Announces Comprehensive Syndromic PCR-Based Testing Approach For Reproductive Tract Infections

Seegene Launches Global Million Clinical Study to Establish Clinical Evidence for Comprehensive Syndromic PCR Testing

Seegene Launches Global Million Clinical Study to Shape New Disease-Specific Testing Standards

Upcoming dividend of ₩200 per share

Seegene Launches Allplex MDRO Assay Under IVDR

Consensus EPS estimates increase by 52%, revenue downgraded

Investor sentiment improves as stock rises 15%

Seegene's (KOSDAQ:096530) Performance Is Even Better Than Its Earnings Suggest

Full year 2025 earnings: EPS misses analyst expectations

Seegene, Inc., Annual General Meeting, Mar 27, 2026

Price target decreased by 8.1% to ₩39,500

Seegene, Inc. to Report Q4, 2025 Results on Feb 25, 2026

Upcoming dividend of ₩200 per share

Seegene (KOSDAQ:096530) Seems To Use Debt Rather Sparingly

Consensus EPS estimates fall by 34%

Seegene Inc. Unveils CURECA™? and STAgora™? At ADLM 2025, Advancing the Next Stage of Diagnostics

Does Seegene (KOSDAQ:096530) Have A Healthy Balance Sheet?

Upcoming dividend of ₩200 per share

Price target increased by 8.9% to ₩43,000

Seegene, Inc. (KOSDAQ:096530) Shares Fly 25% But Investors Aren't Buying For Growth

Seegene Inc. Announces Development of CURECA, A Next-Generation Fully Automated PCR Solution Featuring Customizable Pre- Treatment Automation

Seegene, Inc., Annual General Meeting, Mar 28, 2025

New major risk - Revenue and earnings growth

Seegene, Inc. (KOSDAQ:096530) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Investor sentiment improves as stock rises 22%

Upcoming dividend of ₩200 per share

New major risk - Financial data availability

Investors Shouldn't Be Too Comfortable With Seegene's (KOSDAQ:096530) Earnings

Third quarter 2024 earnings released: EPS: ₩36.00 (vs ₩101 loss in 3Q 2023)

Is Seegene (KOSDAQ:096530) Using Too Much Debt?

Seegene, Inc.(KOSDAQ:A096530) dropped from FTSE All-World Index (USD)

Upcoming dividend of ₩200 per share

Investor sentiment deteriorates as stock falls 16%

Seegene, Inc. Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration

New minor risk - Share price stability

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share

Now 20% overvalued

Upcoming dividend of ₩200 per share

Full year 2023 earnings: EPS and revenues exceed analyst expectations

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

New minor risk - Share price stability

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share at 3.5% yield

Price target decreased by 8.8% to ₩25,000

New minor risk - Share price stability

Upcoming dividend of ₩200 per share at 3.7% yield

Consensus EPS estimates fall from profit to ₩18.00 loss

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Seegene Inc. Unveils Solutions to Popularize Molecular Diagnostics At 2023 AACC

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 30,000 million worth of its shares.

Upcoming dividend of ₩200 per share at 3.7% yield

Upcoming dividend of ₩200 per share at 3.1% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 21%

Upcoming dividend of ₩400 per share

Investor sentiment deteriorated over the past week

Price target decreased to ₩38,667

Less than half of directors are independent

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Upcoming dividend of ₩200 per share

Consensus revenue estimates fall by 24%

Now 20% undervalued

Investor sentiment improved over the past week

Seegene, Inc. to Pave Way for PCR Testing At Local Clinics with EU-Approved Multiplex Test and Fully Automated PCR Solution

Seegene Inc. Develops PCR Test to Detect Monkeypox Virus

Upcoming dividend of ₩400 per share

Now 24% undervalued after recent price drop

Price target decreased to ₩71,500